Maxim Group Maintains Buy Rating for Quoin Pharmaceuticals: Here's What You Need To Know

Maxim Group has decided to maintain its Buy rating of Quoin Pharmaceuticals QNRX and lower its price target from $15.00 to $4.00.

Shares of Quoin Pharmaceuticals are trading up 2.0% over the last 24 hours, at $1.02 per share.

A move to $4.00 would account for a 292.16% increase from the current share price.

About Quoin Pharmaceuticals

Quoin Pharmaceuticals Ltd is a pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.

About Analyst Ratings

Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.

Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.

If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along with analyst success scores in Benzinga Pro.

This article was generated by Benzinga's automated content engine and reviewed by an editor.